<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04846348</url>
  </required_header>
  <id_info>
    <org_study_id>20-011876</org_study_id>
    <nct_id>NCT04846348</nct_id>
  </id_info>
  <brief_title>Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis</brief_title>
  <official_title>An Open-Label Pilot Study to Evaluate the Effectiveness and Tolerability of a Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph Butterfield</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and tolerability of a novel&#xD;
      topical preparation for the treatment of cutaneous lesions of mastocytosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cutaneous symptom relief</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of participants who achieve complete resolution or near-complete clearing of cutaneous symptoms of treated, involved skin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SkinDex-16 Quality of Life</measure>
    <time_frame>Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks</time_frame>
    <description>Change in Skindex-16 score. Skindex-16 is a validated measurement of the effects of skin diseases on patients' quality of life</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cutaneous Mastocytoses</condition>
  <arm_group>
    <arm_group_label>Skin Guard</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Skin cream combination of ingredients includes 2 agents which target mast cell mediators and one agent which globally reduces mast cell degranulation combined in an emollient cream base:&#xD;
Vanicream: Over the counter emollient cream Diphenhydramine Antihistamine Trolamine salicylate Prostaglandin inhibitor, antiinflammatory Cromolyn Sodium Mast cell degranulation inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Topical preparation of sodium cromolyn 5%, diphenhydramine 1% and trolamine salicylate 10% in emollient cream base.</intervention_name>
    <description>Combination of ingredients includes 2 agents which target mast cell mediators and one agent which globally reduces mast cell degranulation combined in an emollient cream base (Vanicream).components: Vanicream: Over the counter emollient cream Diphenhydramine Antihistamine Trolamine salicylate Prostaglandin inhibitor, antiinflammatory Cromolyn Sodium Mast cell degranulation inhibitor</description>
    <arm_group_label>Skin Guard</arm_group_label>
    <other_name>Skin Guard</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Biopsy proven cutaneous mastocytosis with or without evidence of systemic disease&#xD;
&#xD;
          -  Male and female patients 18 to 80 years of age&#xD;
&#xD;
          -  No UVB treatment of the skin for 6 months prior to study entry&#xD;
&#xD;
          -  No use of topical or systemic corticosteroids for 1 month prior to study entry&#xD;
&#xD;
          -  Good general health as confirmed by medical history&#xD;
&#xD;
          -  Female patients of child-bearing potential with negative urine pregnancy test who&#xD;
             agree to use effective methods of birth control or remain abstinent during treatment.&#xD;
             Participants must use birth control for the entire study and for at least 1 week after&#xD;
             the last application of the study formulation. Acceptable methods of birth control&#xD;
             include ongoing hormonal contraception methods, (such as birth control pills, patches,&#xD;
             injections, vaginal ring, or implants), barrier methods (such as a condom (for men) or&#xD;
             diaphragm used with a spermicide), intrauterine devices, tubal ligation, or&#xD;
             abstinence.&#xD;
&#xD;
          -  Patients who are willing and capable of cooperating to the extent and degree required&#xD;
             by the protocol; and&#xD;
&#xD;
          -  Patients who read and sign an approved informed consent for this study&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Vulnerable study population&#xD;
&#xD;
          -  Exposure to ultraviolet B (UVB) radiation to any region of the skin surface for 6&#xD;
             months&#xD;
&#xD;
          -  Regular use of skin lightening agents within 1 month of study entry, including&#xD;
&#xD;
               -  Topical corticosteroids&#xD;
&#xD;
               -  Topical bleaching products&#xD;
&#xD;
               -  Topical retinoids&#xD;
&#xD;
          -  Use of systemic preparations within 1 month of study entry, including:&#xD;
&#xD;
               -  Systemic corticosteroids&#xD;
&#xD;
               -  Systemic cyclosporine, interferon&#xD;
&#xD;
               -  Systemic acitretin, etretinate, isoretinoin&#xD;
&#xD;
               -  Systemic methotrexate,&#xD;
&#xD;
               -  Systemic photoallergic, phototoxic and/or photosensitizing drugs&#xD;
&#xD;
          -  UV light therapy and sunbathing&#xD;
&#xD;
          -  Inability to communicate or cooperate with the Principal Investigator and/or&#xD;
             Investigators due to language problems, poor mental development or impaired cerebral&#xD;
             function&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Women planning a pregnancy within the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Butterfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph H Butterfield, M.D.</last_name>
      <phone>507-284-3783</phone>
      <email>butterfield.joseph@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Joseph Butterfield</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastocytosis</mesh_term>
    <mesh_term>Mastocytosis, Cutaneous</mesh_term>
    <mesh_term>Mastocytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Salicylates</mesh_term>
    <mesh_term>Cromolyn Sodium</mesh_term>
    <mesh_term>Emollients</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

